HGH Fragment 176-191 vs AOD-9604: How the Two Fat-Metabolism GH Fragments Actually Differ

If you have gone looking for a peptide tied to fat metabolism, you have almost certainly run into two names that sound like siblings: HGH Fragment 176-191 and AOD-9604. That is because they nearly are. Both are small pieces of the human growth hormone molecule, both come from the same tail-end region of that hormone, and both are studied for the same narrow question, whether a fragment can influence how the body handles fat without carrying the rest of growth hormone's activity. The confusing part is that they are not two unrelated compounds so much as a fragment and a tweaked version of that fragment. This guide lays out honestly how they relate, where they differ, what the research has actually looked at, and the cons and reported downsides on both sides.

What HGH Fragment 176-191 is

HGH Fragment 176-191 is exactly what the name says: a synthetic copy of the amino acids at positions 176 to 191 of the human growth hormone chain, the very tail end of the 191-amino-acid hormone. Researchers isolated this C-terminal region because early work suggested the fat-metabolism-related activity of growth hormone might be concentrated there, separate from the parts that raise blood sugar or drive general growth. It is a research-grade peptide. It is not FDA-approved for weight loss, body composition, or any other human use, and it is sold for laboratory research purposes only.

What AOD-9604 is

AOD-9604, sometimes written as the anti-obesity drug fragment, is a modified analog of that same 176-191 region. It takes the fragment and adds a small structural change, a tyrosine residue at one end, which was intended to improve the molecule's stability. In other words, AOD-9604 is essentially an engineered descendant of HGH Fragment 176-191 rather than a fully separate discovery. It, too, is a research-grade compound that is not FDA-approved for fat loss or any human indication. We keep a neutral data sheet on it at /peptides/aod-9604, and a fuller verdict deep-dive at /verdicts/aod-9604.

Same class, same origin: why they get confused

The reason these two are so easy to confuse is that they share almost everything that usually distinguishes peptides. Both belong to the same class, growth-hormone C-terminal fragments studied for fat-metabolism effects. Both trace back to the same 176-191 tail region. Both are commonly researched for whether they can influence lipid metabolism, the breakdown of stored fat, without the broader growth-hormone effects such as raising insulin-like growth factor levels or blood glucose. AOD-9604 is best understood as the stabilized, patent-developed version of the raw fragment concept. If you are trying to understand fat-metabolism peptides more broadly, our overview at /learn/peptides-for-weight-loss puts this whole category in context.

What the research has actually looked at

This is where honesty matters most, because the marketing outruns the data for both. AOD-9604 is the more formally studied of the two: it went through clinical development as an anti-obesity candidate, and in that program the human trials measured weight and metabolic endpoints. Importantly, a phase-two trial reported that AOD-9604 did not produce weight loss significantly greater than placebo, which is a large part of why it never became an approved medicine. HGH Fragment 176-191 has far less human evidence than that; much of what is cited for it comes from animal and laboratory work on fat metabolism rather than controlled human trials. So the honest framing is not that one clearly beats the other, but that neither has established the fat-loss benefit people buy them for, and the better-studied of the two actually came up short on its main endpoint. For how to read this kind of trial evidence yourself, see /learn/how-to-read-a-peptide-study.

Regulatory and legal status: the same gray zone

On status, the two are essentially identical, and it is not a flattering picture for either. HGH Fragment 176-191 is not FDA-approved as a drug for weight loss or any other condition, and AOD-9604 is not FDA-approved either. Both are sold under research-use-only labeling, are not lawful supplements or medicines for the uses buyers intend, and their legality varies by jurisdiction. Anti-doping authorities also list growth-hormone fragments as prohibited substances in sport. This is the same regulatory gray zone that surrounds most research peptides, and we cover the wider picture in our legality guide at /learn/is-my-peptide-legal-2026.

The cons and reported side effects on both sides

Because the two are so chemically close, their downsides overlap heavily, and neither is consequence-free. Reported and possible effects for both fragments include injection-site reactions, headaches, and, because these are unapproved compounds, a simply incomplete long-term safety picture, since the large multi-year human trials that would characterize it have not been run. For AOD-9604 specifically, the clinical program did track adverse events, but the absence of a demonstrated benefit means the risk-versus-reward math never favored it. The most underrated con for both is not the molecule at all but the supply: research-grade vials from the gray market can be underdosed, mislabeled, or contaminated with endotoxins or heavy metals, because no regulator verifies what is actually inside them. We keep a running summary of these issues at /learn/common-peptide-side-effects.

So which one should you care about?

Framing this as HGH Fragment 176-191 versus AOD-9604 in a winner-take-all sense slightly misses the point, because they are close relatives rather than rivals. AOD-9604 is the more developed, more formally tested version of the same 176-191 fragment idea, so if you want to know what the better human evidence says, its trial record is the one to read, and that record is underwhelming on the main weight endpoint. HGH Fragment 176-191 is the rawer, less-studied parent concept with thinner human data behind it. For either, the honest bottom line is the same: an interesting piece of growth-hormone biology, a lot of marketing layered on top of it, and a human evidence base that has not matched the fat-loss result the ads imply. If you are weighing peptides against actual growth hormone rather than each other, our companion guide at /learn/peptides-vs-hgh-injections draws that separate line.

References & sources

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278.
2. Heffernan MA, Summers RJ, Thorburn AW, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
3. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther. 2010;87(6):652-662. Reports that AOD9604 development was terminated in 2007 after it failed to induce significant weight loss in a 24-week trial of 536 subjects.
4. World Anti-Doping Agency. The Prohibited List: peptide hormones, growth factors, related substances and mimetics (S2), which includes growth hormone (GH), its analogues and fragments (S2.2.3).
5. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — on unapproved drugs falsely labeled "for research purposes" / "not for human consumption" that bypass FDA review for safety, quality, and content.